Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Status:
Recruiting
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial studies how well dexrazoxane hydrochloride works in preventing
heart-related side effects of chemotherapy in participants with blood cancers, such as acute
myeloid leukemia, myelodysplastic syndrome, chronic myeloid leukemia, and myeloproliferative
neoplasms. Chemoprotective drugs, such as dexrazoxane hydrochloride, may protect the heart
from the side effects of drugs used in chemotherapy, such as cladribine, idarubicin,
cytarabine, and gemtuzumab ozogamicin, in participants with blood cancers.